Literature DB >> 8198393

Cellular and molecular biology of Alzheimer's disease and animal models.

D L Price1, S S Sisodia.   

Abstract

Alzheimer's disease (AD), the most common dementing disorder of late life, is a major cause of disability and death in the elderly. Neurobiological, genetic, and molecular studies have defined the vulnerable neural systems, abnormalities in cytoskeletal proteins in neurons, the biology of the beta-amyloid precursor protein (APP) and beta-amyloid (A beta, beta A4), and several APP mutations linked to the disease. More recently, investigators have begun to develop animal models essential for delineating pathogenetic mechanisms and for developing and testing new therapies for treating AD in humans. This review focuses primarily on recent progress in investigation of animal models of AD (including aged nonhuman primates and transgenic mice), which have begun to clarify some of the questions raised by investigation of the disease in humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198393     DOI: 10.1146/annurev.med.45.1.435

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  42 in total

Review 1.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Progress in researches on the effect of acupuncture in antagonizing oxygen stress.

Authors:  Zhong-ren Li; Mei-hong Shen; Yong-jun Peng
Journal:  Chin J Integr Med       Date:  2005-06       Impact factor: 1.978

3.  Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein.

Authors:  F Zhang; C Eckman; S Younkin; K K Hsiao; C Iadecola
Journal:  J Neurosci       Date:  1997-10-15       Impact factor: 6.167

4.  Neurotoxic effects induced by the Drosophila amyloid-beta peptide suggest a conserved toxic function.

Authors:  Katia Carmine-Simmen; Thomas Proctor; Jakob Tschäpe; Burkhard Poeck; Tilman Triphan; Roland Strauss; Doris Kretzschmar
Journal:  Neurobiol Dis       Date:  2008-11-08       Impact factor: 5.996

5.  Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.

Authors:  Anahit Ghochikyan; Mikayel Mkrtichyan; Irina Petrushina; Nina Movsesyan; Adrine Karapetyan; David H Cribbs; Michael G Agadjanyan
Journal:  Vaccine       Date:  2005-12-05       Impact factor: 3.641

Review 6.  Age-related alteration of PKC, a key enzyme in memory processes: physiological and pathological examples.

Authors:  A Pascale; S Govoni; F Battaini
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

Review 7.  Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

Authors:  David H Cribbs
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 8.  Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines.

Authors:  Hayk Davtyan; Andrew Bacon; Irina Petrushina; Karen Zagorski; David H Cribbs; Anahit Ghochikyan; Michael G Agadjanyan
Journal:  Hum Vaccin Immunother       Date:  2014-02-13       Impact factor: 3.452

9.  Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys.

Authors:  Alvin V Terry; Marc Plagenhoef; Patrick M Callahan
Journal:  Psychopharmacology (Berl)       Date:  2015-11-27       Impact factor: 4.530

10.  Natural non-trasgenic animal models for research in Alzheimer's disease.

Authors:  Manuel Sarasa; Pedro Pesini
Journal:  Curr Alzheimer Res       Date:  2009-04       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.